Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Zealand Pharma Ord Shs ZLDPF

Healthcare Biotechnology

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline... see more

Add To Watchlist

Recent & Breaking News (PINL:ZLDPF)

Update: Zealand Pharma hosts conference call on March 12 at 4 pm CET (11 am EDT) to present full year results for 2019

GlobeNewswire March 9, 2020

Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019

GlobeNewswire February 26, 2020

Zealand Pharma to attend 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 20, 2020

Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism

GlobeNewswire December 4, 2019

Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment

GlobeNewswire November 14, 2019

Bernadette Connaughton Appointed to Syneos Health Board of Directors

GlobeNewswire November 12, 2019

Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019

GlobeNewswire October 28, 2019

Zealand Pharma expands its peptide platform with acquisition of Encycle Therapeutics

GlobeNewswire October 22, 2019

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

GlobeNewswire September 24, 2019

Zealand Pharma completes subscription of new shares and registration of capital increase

GlobeNewswire September 11, 2019

Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 559.6 million

GlobeNewswire September 5, 2019

Zealand Pharma to attend Morgan Stanley 17th Annual Global Healthcare Conference

GlobeNewswire August 29, 2019

Correction: Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer

GlobeNewswire August 28, 2019

Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer

GlobeNewswire August 28, 2019

Zealand Pharma relocates headquarters to accommodate growth

GlobeNewswire August 27, 2019

Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S.

GlobeNewswire August 15, 2019

Zealand Pharma hosts conference call on August 15 at 4 pm CET (10 am EST) to present first half results for 2019

GlobeNewswire August 1, 2019

Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome

GlobeNewswire June 26, 2019

Zealand Pharma introduces new website to support people living with short bowel syndrome

GlobeNewswire June 21, 2019

Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)

GlobeNewswire June 10, 2019